PD-L1 and Tumor infiltrating lymphocytes as prognostic markers in resected NSCLC

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Ameratunga, Malaka ^a   Asadi, Khashayar ^a   Lin, Xihui ^b   Walkiewicz, Marzena ^c   Murone, Carmel ^a,c   Knight, Simon ^a   Mitchell, Paul ^a   Boutros, Paul ^b,d,e   John, Thomas ^a,c,f,g  

^a AUSTIN HEALTH   (Australia)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^c OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f LA TROBE UNIVERSITY   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR FOXP3; VASCULOTROPIN RECEPTOR; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DISEASE MARKER; EGFR GENE; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KRAS GENE; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; SQUAMOUS CELL LUNG CARCINOMA; STROMA; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

AGED; ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84977649687     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153954     Document Type: Article

References (49)

1. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. doi: 10.1126/science.aaa1348 PMID: 25765070
2. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2015.
3. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. New England Journal of Medicine. 2013; 369(2):122-33. doi: 10.1056/ NEJMoa1302369 PMID: 23724867
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine. 2010; 363 (8):711-23. doi: 10.1056/NEJMoa1003466 PMID: 20525992
5. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Journal of Clinical Oncology. 2015:JCO. 2014. 58. 3377.
6. Loke PN, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proceedings of the National Academy of Sciences. 2003; 100(9):5336-41.
7. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund L-T. Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non-Small Cell Lung Cancer. Clinical Cancer Research. 2008; 14(16):5220-7. doi: 10.1158/1078-0432.CCR-08-0133 PMID: 18698040
8. Donnem T, Hald SM, Paulsen E-E, Richardsen E, Al-Saad S, Kilvaer TK, et al. Stromal CD8+ T Cell Density-A Promising Supplement to TNM staging in Non-Small Cell Lung Cancer. Clinical Cancer Research. 2015:clincanres. 1905.2014.
9. Dieu-Nosjean M-C, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. Journal of Clinical Oncology. 2008; 26(27):4410-7. doi: 10.1200/JCO.2007.15.0284 PMID: 18802153
10. Tian C, Lu S, Fan Q, Zhang W, Jiao S, Zhao X, et al. Prognostic Significance of Tumor-infiltrating CD8+ or CD3+ T Lymphocytes and Interleukin-2 Expression in Radically Resected Non-small Cell Lung Cancer. Chinese medical journal. 2015; 128(1):105. doi: 10.4103/0366-6999.147828 PMID: 25563322
11. Ishibashi Y, Tanaka S, Tajima K, Yoshida T, Kuwano H. Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm. Oncology reports. 2006; 15(5):1315-9. PMID: 16596204
12. Tao H, Shien K, Soh J, Matsuda E, Toyooka S, Okabe K, et al. Density of Tumor-Infiltrating FOXP3+ T Cells as a Response Marker for Induction Chemoradiotherapy and a Potential Prognostic Factor in Patients Treated with Trimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer. Annals of Thoracic and Cardiovascular Surgery. 2014.
13. Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cellular & molecular immunology. 2010; 7(5):389-95.
14. Suzuki K, Kadota K, Sima CS, Nitadori J-i, Rusch VW, Travis WD, et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. Journal of Clinical Oncology. 2013; 31(4):490-8. doi: 10.1200/JCO.2012.45.2052 PMID: 23269987
15. Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, et al. Objective Measurement and Clinical Significance of TILs in Non-Small Cell Lung Cancer. Journal of the National Cancer Institute. 2015; 107(3). doi: 10.1093/jnci/dju435
16. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, et al. Concurrent infiltration by CD8 + T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. British journal of cancer. 2006; 94(2):275-80. PMID: 16421594
17. Horne ZD, Jack R, Gray ZT, Siegfried JM, Wilson DO, Yousem SA, et al. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. Journal of Surgical Research. 2011; 171(1):1-5. doi: 10.1016/j.jss.2011.03.068 PMID: 21571304
18. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008; 113(6):1387-95. Epub 2008/08/02. doi: 10.1002/cncr.23712 PMID: 18671239.
19. Kilic A, Landreneau RJ, Luketich JD, Pennathur A, Schuchert MJ. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. Journal of Surgical Research. 2011; 167(2):207-10. doi: 10.1016/j.jss.2009.08.029 PMID: 19896677
20. Liu H, Zhang T, Ye J, Li H, Huang J, Li X, et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunology, Immunotherapy. 2012; 61(10):1849-56. PMID: 22456757
21. Mori M, Ohtani H, Naito Y, Sagawa M, Sato M, Fujimura S, et al. Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. The Tohoku journal of experimental medicine. 2000; 191(2):113-8. PMID: 10946920
22. Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH, et al. Tumor infiltrating Foxp3 + regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006; 107(12):2866-72. PMID: 17099880
23. Tian C, Lu S, Fan Q, Zhang W, Jiao S, Zhao X, et al. Prognostic Significance of Tumor-infiltrating CD8 (+) or CD3 (+) T Lymphocytes and Interleukin-2 Expression in Radically Resected Non-small Cell Lung Cancer. Chinese medical journal. 2015; 128(1):105-10. Epub 2015/01/08. doi: 10.4103/0366-6999. 147828 PMID: 25563322.
24. Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human nonsmall cell lung cancers. Cancer science. 2003; 94(11):1003-9. Epub 2003/11/13. PMID: 14611679.
25. Zhang G-Q, Han F, Fang X-Z, Ma X-M. CD4+, IL17 and Foxp3 expression in different pTNM stages of operable non-small cell lung cancer and effects on disease prognosis. Asian Pac J Cancer Prev. 2012; 13(8):3955-60. PMID: 23098499
26. Zhuang X, Xia X, Wang C, Gao F, Shan N, Zhang L, et al. A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Applied Immunohistochemistry & Molecular Morphology. 2010; 18(1):24-8.
27. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. doi: 10.1038/ nature13954 PMID: 25428505
28. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of surgical oncology. 2010; 17(6):1471-4. doi: 10.1245/ s10434-010-0985-4 PMID: 20180029
29. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). British journal of cancer. 2005; 93(4):387-91. PMID: 16106245
30. Zhang Y, Wang L, Li Y, Pan Y, Wang R, Hu H, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco-Targets and therapy. 2014; 7:567. doi: 10.2147/OTT.S59959 PMID: 24748806
31. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. Clinical Cancer Research. 2014; 20(19):5064-74. doi: 10.1158/1078-0432.ccr-13-3271 PMID: 24714771
32. Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, et al. Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM). PloS one. 2014; 10(3):e0121071-e.
33. D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. British journal of cancer. 2015; 112 (1):95-102. doi: 10.1038/bjc.2014.555 PMID: 25349974
34. Antonia SJ, Gettinger S, Chow LQ, Juergens R, Borghaei H, Shen Y, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line non-small cell lung cancer (NSCLC): interim phase 1 results. Journal of clinical oncology. 2014; 32.
35. Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Physical therapy. 2005; 85(3):257-68. PMID: 15733050
36. John T, Starmans M, Chen Y-T, Russell PA, Barnett SA, White SC, et al. The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. PloS one. 2013; 8(7):e67876. doi: 10.1371/journal.pone.0067876 PMID: 23935846
37. Kerr KM, Tsao M-S, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR, et al. PD-L1 immunohistochemistry in lung cancer: in what state is this art? Journal of Thoracic Oncology. 9000;Publish Ahead of Print. doi: 10.1097/jto.0000000000000526 PMID: 01243894-900000000-98972.
38. Schmidt LH, Kummel A, Gorlich D, Mohr M, Brockling S, Mikesch JH, et al. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS One. 2015; 10(8):e0136023. Epub 2015/08/28. doi: 10.1371/journal.pone.0136023 PMID: 26313362; PubMed Central PMCID: PMCPmc4552388.
39. Pan Z-K, Ye F, Wu X, An H-X, Wu J-X. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. Journal of thoracic disease. 2015; 7(3):462. doi: 10.3978/j.issn.2072-1439.2015.02.13 PMID: 25922726
40. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clinical Cancer Research. 2004; 10(15):5094-100. PMID: 15297412
41. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Laboratory Investigation. 2013; 94(1):107-16. doi: 10.1038/labinvest.2013.130 PMID: 24217091
42. Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer. (0: ). http://dx.doi.org/ 10.1016/j.lungcan.2015.05.007.
43. Zhang Y, Kang S, Shen J, He J, Jiang L, Wang W, et al. Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer: A Meta-Analysis. Medicine. 2015; 94(6):e515. doi: 10.1097/MD.0000000000000515 PMID: 25674748
44. Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Annals of Oncology. 2014; 25(10):1935-40. doi: 10.1093/annonc/mdu242 PMID: 25009014
45. Kim M-Y, Koh J, Kim S, Go H, Jeon YK, Chung DH. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer. 88(1):24-33. doi: 10.1016/j.lungcan.2015.01.016 PMID: 25662388
46. Boland JM, Kwon ED, Harrington SM, Wampfler JA, Tang H, Yang P, et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clinical lung cancer. 2013; 14(2):157-63. doi: 10. 1016/j.cllc.2012.05.006 PMID: 22868219
47. Yang C-Y, Lin M-W, Chang Y-L, Wu C-T, Yang P-C. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. European Journal of Cancer. 2014; 50(7):1361-9. doi: 10.1016/j.ejca.2014.01.018 PMID: 24548766
48. Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. British journal of cancer. 2011; 105(1):93-103. doi: 10.1038/bjc.2011.189 PMID: 21629244
49. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012; 10(1):1.